{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:41Z","timestamp":1778889761752,"version":"3.51.4"},"reference-count":12,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B-cell lymphoma for which no optimal treatment has been established and prognosis remains poor. Here, we describe a human immunodeficiency virus-uninfected patient with PBL that was refractory to conventional chemotherapies but was successfully controlled with a bortezomib-based regimen followed by a lenalidomide-based regimen. &lt;b&gt;&lt;i&gt;Case Presentation:&lt;\/i&gt;&lt;\/b&gt; A 64-year-old man suffered from nasal bleeding and occlusion. Whole-body computed tomography results revealed a large lesion occupying his nasal cavity. He was diagnosed with PBL based on a tumor biopsy and was treated with two lines of conventional chemotherapy. A dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) regimen and an ifosfamide, carboplatin, and etoposide (ICE) regimen were ineffective, but the bortezomib-based regimen CyBorD (bortezomib, cyclophosphamide orally, and dexamethasone orally) provided a clinical response. Due to peripheral neuropathy, the patient was then treated with a lenalidomide-based regimen (Ld; lenalidomide and dexamethasone). Although a complete response was not achieved, the Ld regimen was tolerated and was continued with a partial response (PR) for over 2 years. &lt;b&gt;&lt;i&gt;Discussion\/Conclusion:&lt;\/i&gt;&lt;\/b&gt; In the present case, PBL that was refractory to conventional chemotherapies responded to the CyBorD regimen and a long-term Ld-based regimen without severe adverse effects. This strategy provided and maintained a PR for over 2 years. Despite not resulting in tumor reduction and only maintaining a PR, continued Ld treatment contributed to long-term survival of the present patient with PBL.<\/jats:p>","DOI":"10.1159\/000504608","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T22:00:35Z","timestamp":1576533635000},"page":"112-116","source":"Crossref","is-referenced-by-count":28,"title":["Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma"],"prefix":"10.1159","volume":"43","author":[{"given":"Koji","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Niino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makio","family":"Hourai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sawayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.4.1413"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21250"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005981"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh399"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27551"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.009"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199679"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2732-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000350325"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15156"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.3808"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:12:53Z","timestamp":1745424773000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000504608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,3,11]]}},"URL":"https:\/\/doi.org\/10.1159\/000504608","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]}}}